Karo Pharma AB (Karo Pharma AB) Debt-to-Equity : 1.06 (As of Jun. 2022)

Karo Pharma AB Debt-to-Equity Chart

Karo Pharma AB Annual Data
	Trend	Dec12	Dec13	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21
Debt-to-Equity		Get a 7-Day Free Trial					1.43	0.80	0.77	1.04	0.99

Karo Pharma AB Quarterly Data
	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Jun22
Debt-to-Equity	Get a 7-Day Free Trial															1.02	1.09	1.03	0.99	1.06

Competitive Comparison of Karo Pharma AB's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Karo Pharma AB's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Karo Pharma AB's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Karo Pharma AB's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Karo Pharma AB's Debt-to-Equity falls into.

Karo Pharma AB Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Karo Pharma AB's Debt to Equity Ratio for the fiscal year that ended in Dec. 2021 is calculated as

Karo Pharma AB's Debt to Equity Ratio for the quarter that ended in Jun. 2022 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Karo Pharma AB  (OTCPK:KARBF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Karo Pharma AB Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Karo Pharma AB's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Karo Pharma AB (Karo Pharma AB) Business Description